Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein O (FOXO) transcription factor (FOXO (in mammals); DAF-16 (in *Caenorhabditis elegans*))
- Target
- FOXO (in mammals); DAF-16 (in *Caenorhabditis elegans*)
- Molecular classification
- Transcription factor, Forkhead family (class O)
01
Overview
DAF-16/FOXO transcription factor is a major regulator of stress response, longevity, metabolism, cell cycle arrest, and apoptosis. In *C. elegans*, DAF-16 is the sole FOXO ortholog, while mammals have four FOXO proteins (FOXO1, FOXO3, FOXO4, FOXO6). DAF-16/FOXO binds to DNA at specific consensus sites (DAF-16 Binding Element, TTGTTTAC), regulating diverse genes in pathways controlling development, metabolism, lifespan, and resistance to environmental stresses. DAF-16/FOXO activity is tightly controlled by upstream signaling, particularly insulin/IGF-1 signaling, and post-translational modifications like phosphorylation and acetylation. Its regulatory module can interact with other transcription factors (e.g., HLH-30/TFEB), and it is of central interest in aging, cancer, and metabolic disease biology.
- Other names
- DAF-16FOXO (generic for Forkhead box protein O family in mammals)FKHR (FOXO1)FKHRL1 (FOXO3)AFX (FOXO4) in mammals
02
Mechanism of action
Activation/inhibition of DAF-16/FOXO through modulation of upstream signaling pathways (mainly insulin/IGF-1 signaling; SIRT1-mediated deacetylation). Drugs targeting DAF-16/FOXO typically regulate its post-translational modifications, nuclear translocation, and ability to bind to the DAF-16 Binding Element (DBE) of target genes.
03
Biological functions
Stress resistanceCell cycle arrestApoptosisLongevity regulationMetabolism regulationDNA damage responseImmune response
04
Disease associations
Cancer (tumor suppression, apoptosis)Aging (longevity)InflammationNeurodegenerative disease (protective roles)Metabolic disorders (diabetes, insulin signaling)Infection (immune regulation)
05
Safety considerations
Therapeutic modulation of FOXO proteins may influence cancer risk, aging, or metabolic side effects, given their broad regulatory rolesOff-target effects possible due to widespread involvement in cell cycle and apoptosis
06
Interacting drugs
Specific small molecules targeting FOXO function or its pathway remain largely experimental; sirtuin agonists/activators have shown indirect interaction (such as SIRT1 modulation of FOXO)
1 more in the full profile.
07
Biomarkers
Expression levels/nuclear localization of DAF-16/FOXO proteinsTranscriptional activity of target genes (e.g., *sod-3*, *mtl-1*, *hsp-12.6*, *daf-15*)Downstream markers: stress response genes, antioxidant enzymes, and metabolic regulators
Beyond the preview
Go deeper on Forkhead box protein O (FOXO) transcription factor (FOXO (in mammals); DAF-16 (in *Caenorhabditis elegans*)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forkhead box protein O (FOXO) transcription factor (FOXO (in mammals); DAF-16 (in *Caenorhabditis elegans*)).